New hope for deadly childhood brain cancer? experimental drug tested with radiation
NCT ID NCT01165333
Summary
This study aimed to find the safest dose of an experimental drug called Cilengitide when given alongside standard radiation therapy. It involved 32 children and young adults newly diagnosed with a rare and aggressive brain stem tumor. The main goal was to see if this drug combination was tolerable, as a first step toward finding a more effective treatment for this devastating disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE, INTRINSIC PONTINE GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU
Toulouse, 33059, France
-
CHU, Hôpital d'Enfants de la Timone
Marseille, 13385, France
-
Centre Hospitalier Universitaire de Nantes
Nantes, 44093, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Hôpital des Enfants, Groupe Hospitalier
Bordeaux, 33076, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
Institut Curie
Paris, 75231, France
-
Institut Gustave-Roussy
Villejuif, 94805, France
Conditions
Explore the condition pages connected to this study.